Pixelgen will use the financing to expand the applications of its Pixelgen Proxiome Kit, launched earlier this year as the first kit and software for protein interactome analysis of single cells at high capacity, it states.

“We’re thrilled to receive this highly competitive funding from the EIC,” said Pixelgen co-founder and CEO Simon Fredriksson. “The process was rigorous, and the award further reinforces the value of Pixelgen’s technology to increase our understanding of complex cellular and functional cell surface arrangements, which we believe will advance drug development and deepen our understanding of precision medicine. The response from leading researchers in industry and academia to our Proxiome Kit has been very enthusiastic, and this grant will help accelerate its expansion into new applications, including cell-to-cell interactions, communication, and FFPE tissues.”

The EIC selected 40 innovative start-ups and small-to-medium-sized enterprises out of 150 applicants in its latest evaluation round to receive funding. The companies were chosen for their “transformative technologies and strong commercial promise,” according to the EIC.